The American Journal of Medical Sciences and Pharmaceutical Research
ISSN 2689-1026 | Open Access

TYPE Original Research
PAGE NO. 15-21
DOI 10.37547/tajmspr/Volume07Issue07-03

Generative AI In Life Sciences: Unlocking Operational Value Across the Product Lifecycle

Efim Iuresku
Engagement Manager, Strategic Consulting Firm
New York City, USA

OPEN ACCESS

SUBMITED 07 June 2025
ACCEPTED 24 June 2025
PUBLISHED 26 July 2025
VOLUME Vol.07 Issue 07 2025

CITATION

Efim Iuresku. (2025). Generative AI In Life Sciences: Unlocking Operational Value Across the Product Lifecycle. The American Journal of Medical Sciences and Pharmaceutical Research, 7(07), 15–21. https://doi.org/10.37547/tajmspr/Volume07Issue07-03

Abstract: The development and commercialization of pharmaceutical and MedTech products represent one of the most complex and resource-intensive endeavors in the modern economy. The process involves long timelines, high attrition rates, and the integration of vast volumes of structured and unstructured data. Generative artificial intelligence (GenAI) has emerged as a transformative tool capable of enhancing efficiency, accelerating scientific discovery, and streamlining operations across the life sciences value chain - from early research to clinical development, manufacturing, medical affairs, and commercialization.

A synthesis of current literature, real-world implementations, and industry benchmarks was conducted to evaluate high-impact application areas of GenAI in life sciences. Documented use cases from biopharmaceutical and MedTech organizations illustrate the deployment of GenAI in target identification, de novo molecule generation, trial protocol design, medical writing automation, manufacturing deviation analysis, medical engagement support, and omnichannel content generation.

Estimates indicate that GenAI could unlock between $60 billion and $110 billion in annual value across the pharmaceutical industry. The greatest economic potential lies in commercial functions, followed by research and clinical development. Early adopters - including Pfizer, Novartis, AstraZeneca, and Novo Nordisk - have reported productivity improvements ranging from 20% to 60% in pilot programs focused on regulatory documentation, manufacturing quality, and HCP engagement.

Despite these benefits, large-scale adoption remains constrained by several challenges. Key barriers include hallucination risks in language models, regulatory ambiguity, limitations in technical infrastructure and data quality, and resistance to organizational change. Addressing these constraints will be critical to ensuring the safe, compliant, and impactful integration of GenAI technologies into life sciences workflows.

Keywords: Generative AI; Life sciences; Pharmaceutical operations; Pharma digital transformation

1. Introduction

The development and commercialization of pharmaceutical and MedTech products is among the most complex and data-intensive undertakings in the modern economy. Spanning over a decade, involving billions of dollars in investment, and requiring navigation through rigorous scientific, regulatory, operational, and commercial hurdles, the process is inherently high-risk and high-cost. Companies must synthesize vast volumes of structured and unstructured data - from genomic sequences and digital pathology slides to clinical trial reports, supply chain metrics, and real-world patient data - across siloed systems and globally distributed teams.

In this environment, Generative AI (GenAI) has emerged as a transformative technology with the potential to fundamentally reshape how organizations discover, develop, and deliver therapies. Unlike traditional analytical AI, which has already shown impact through classification and prediction tasks, GenAI introduces novel capabilities such as large-scale content generation, synthesis of scientific literature, intelligent summarization, and deep pattern recognition across heterogeneous datasets. These capabilities are particularly valuable in life sciences, where the ability to navigate scientific complexity, accelerate decision-making, and automate labor-intensive knowledge work is a strategic differentiator [1].

Early adopters of GenAI in pharma have focused on target identification and molecular design, but the opportunity extends much further. Real-world pilots now demonstrate impact in clinical development, regulatory submission preparation, manufacturing deviation management, supply chain optimization, medical content generation, and even commercial personalization at scale [1][2].

However, capturing this value is far from plug-and-play. The successful application of GenAI depends not only on the quality of foundation models, but also on the readiness of underlying data architectures, the ability to embed new workflows into operating models, and the strength of governance frameworks addressing regulatory, ethical, and security risks [9].

This article explores the most promising applications of GenAI across the life sciences value chain. Drawing on proprietary insights, industry case examples, and emerging benchmarks, we provide a high-level framework to assess where GenAI can unlock meaningful value - from R&D to market - and how companies can approach adoption responsibly and effectively [2][3].

2. Materials and Methods

This article synthesizes insights from recent external publications, scientific literature, and publicly disclosed examples of Generative AI (GenAI) adoption across the life sciences industry. The analysis is structured around five stages of the pharmaceutical and MedTech value chain: research and early discovery, clinical development, manufacturing and supply chain, medical affairs, and commercialization.

Use cases were selected based on clear evidence of real-world implementation, business relevance, and availability of verifiable impact metrics. Preference was given to examples disclosed by leading organizations in the industry, including pharmaceutical, biotechnology, and medical device companies, through corporate websites, investor briefings, and regulatory filings.

To ensure a comprehensive and balanced perspective, findings were triangulated across academic journals, official regulatory reports, and strategic insights published by consulting firms and technology providers. The goal was to capture both the potential and practical limitations of GenAI adoption in highly regulated, data-intensive environments.

3. Functional Impact of GenAI in Life Sciences

Generative AI (GenAI) is expected to generate between $60 billion and $110 billion in annual value across the pharmaceutical industry value chain [1]. The projected value is not uniformly distributed; instead, it varies by

function depending on task structure, data intensity, and existing digital maturity *(see Figure 1)*.



Figure 1. Expected GenAI impact for Life Sciences

The greatest value potential lies in commercial functions ($18-30B), followed by research and early discovery ($15-28B), clinical development ($13-25B), enterprise functions such as IT, finance, and legal ($8-16B), operations ($4-7B), and medical affairs ($3-5B) [1][7]. This distribution reflects not only the scale of these functions but also the breadth of high-frequency, high-leverage use cases well suited for GenAI technologies.

Importantly, these value estimates are grounded in tangible early outcomes. For example, in R&D, GenAI applications have reduced molecule design cycles by over 50% and improved the probability of clinical trial success by 10% or more. In operations and manufacturing, deviation root-cause analysis, predictive maintenance, and quality reviews have been streamlined, resulting in up to 40%-time savings. In commercial and medical domains, productivity gains of 20-80% have been reported in content generation, field medical support, and customer engagement [1][3][5].

The following sections explore these functional domains in greater depth, highlighting 3-4 of the most promising application areas in each, accompanied by real-world use cases where available.

3.1 Research and Early Discovery

Research and early discovery remain one of the most active and high-potential areas for GenAI deployment in life sciences. With an estimated value potential of $15–28 billion annually [1], this phase benefits from the convergence of complex multimodal data (e.g., omics, literature, structures), computational modeling, and high failure rates - conditions well suited for GenAI-driven acceleration and augmentation.

Key Application Areas

1. **Target identification and indication expansion** *(understand disease mechanisms)*
   Multi-modal foundation models are used to analyze disease biology by synthesizing omics data, scientific literature, and clinical evidence. This enables the identification of novel therapeutic targets and indication repurposing opportunities, particularly for complex or rare conditions [1][5].
2. **In silico compound screening** *(prioritize best-fit molecules)*
   GenAI enables AI-driven prioritization of large compound libraries by simulating target interactions, predicting binding affinity, and identifying toxicity risks. This significantly accelerates early filtering of viable candidates before synthesis [1][5].
3. **De novo molecule generation** *(design novel compounds from scratch)*
   Foundation models trained on chemical and biological data can propose entirely new molecules optimized for specific targets. These models integrate chemical logic, 3D structural data, and pharmacological constraints to accelerate discovery and reduce wet-lab cycles [3][5].
4. **Self-driving laboratories and design loops** *(automate and optimize experimentation)*
   GenAI is increasingly integrated with robotic

platforms to create closed-loop R&D systems. Models suggest next experiments, update hypotheses in real time, and drive faster iteration through AI-guided synthesis and testing.

Illustrative Use Case

A publicly known example is Insilico Medicine, which applied GenAI to accelerate both target identification and molecular design for idiopathic pulmonary fibrosis. Using its proprietary Chemistry42 platform, the company progressed a novel compound from target discovery to IND submission in under 18 months - demonstrating a substantial reduction in early discovery timelines [10]

3.2 Clinical Development

Clinical development accounts for a significant portion of pharmaceutical R&D costs and timelines, often stretching over 6–8 years with high failure rates and substantial operational complexity. GenAI offers opportunities to reduce cost, increase trial success probability, and accelerate timelines through automation, insight generation, and dynamic process optimization. The estimated annual value potential in this domain is $13–25 billion [1].

Key Application Areas

1. **Protocol design and feasibility assessment** *(optimize study setup)*
   GenAI models can synthesize historical trial data, scientific literature, and real-world evidence to generate or optimize trial protocols. They help assess inclusion/exclusion criteria, suggest endpoints, and simulate feasibility across geographies and populations [1][7].
2. **Patient recruitment and site selection** *(improve targeting and speed up enrollment)*
   By analyzing EMRs, prior recruitment performance, and demographic data, GenAI can help identify optimal sites and patient cohorts, reducing recruitment timelines and improving trial diversity [1][7].
3. **Medical writing and submission preparation** *(automate regulatory documents)*
   Large language models can draft clinical study reports (CSRs), investigator brochures, and submission dossiers based on structured trial outputs and pre-trained regulatory formats. This reduces time-to-submission and documentation burden [5][7].
4. **Adverse event detection and monitoring** *(enhance patient safety through signal analysis)*
   GenAI can synthesize patient records, trial monitoring data, and external safety databases to detect potential adverse event patterns in near real-time, allowing for earlier interventions and improved pharmacovigilance [5][7].

Illustrative Use Case

Pfizer has piloted GenAI tools to streamline the drafting of clinical study reports and investigator brochures. These tools integrate structured trial data, statistical outputs, and standard regulatory language formats. Initial results demonstrated a reduction in preparation time of up to 40%, along with improved consistency and reduced burden on regulatory staff [11].

3.3 Manufacturing and Supply Chain

Pharmaceutical and MedTech manufacturing operates under strict regulatory oversight, high batch complexity, and long lead times. Supply chains are global, often fragmented, and vulnerable to disruption. GenAI provides a unique opportunity to enhance visibility, accelerate root-cause analysis, reduce downtime, and optimize inventory - all within validated environments. Estimated value potential: $4–7 billion annually [1].

Key Application Areas

1. **Deviation investigation and root-cause analysis** *(accelerate issue resolution)*
   GenAI models trained on historical deviation logs, batch records, and operator notes can suggest likely root causes of deviations and propose mitigation strategies in real time [3][5][8].
2. **Predictive maintenance and asset optimization** *(prevent equipment failures)*
   By analyzing IoT sensor data, maintenance logs, and process performance, GenAI can forecast equipment failures and optimize service schedules, reducing unplanned downtime and improving throughput [3][5][8].
3. **Batch record review and release automation** *(streamline QA/QC processes)*
   LLMs can analyze batch documentation for

completeness and anomalies, flag inconsistencies, and pre-generate QA summaries, significantly accelerating batch release without compromising compliance [3][5][8].

4. **Supply chain forecasting and scenario planning** *(increase resilience and service levels)* GenAI supports scenario-based planning by generating demand forecasts, risk models, and response strategies based on market signals, production constraints, and historical disruptions.

Illustrative Use Case

Novartis has implemented GenAI-powered digital twins across several manufacturing sites to model process behavior, predict deviations, and support proactive decision-making. In one pilot, the company combined process data with GenAI tools to detect quality risks early and recommend control adjustments - resulting in a reported 30% reduction in batch deviations and 15% improvement in release cycle time [12].

3.4 Medical Affairs

Medical affairs plays a critical role in bridging scientific knowledge with clinical practice and engaging healthcare professionals (HCPs) with credible, timely, and personalized information. However, this function is often constrained by fragmented data, manual content generation, and inconsistent medical engagement. GenAI has the potential to significantly enhance scientific communication, reduce time-to-response, and scale personalized interactions. Estimated value potential: $3–5 billion annually [1].

Key Application Areas

1. **Medical content generation and summarization** *(scale high-quality materials faster)* GenAI can synthesize clinical publications, internal data, and guidelines to generate or update slide decks, FAQs, standard response letters, and MSL materials - freeing up medical staff for high-value work [3][4].
2. **HCP engagement and question response** *(enable real-time, personalized interactions)* Virtual medical copilots powered by GenAI can support MSLs during field visits or serve as self-service channels for HCPs, providing on-demand, evidence-based answers tailored to specialty and context [3][4].

Illustrative Use Case

AstraZeneca has deployed GenAI-powered tools to support its medical affairs teams in generating scientific content and answering complex HCP questions. In pilot programs, these tools produced field-ready materials 60% faster and enabled real-time support during MSL engagements. The company also reported increased consistency in messaging and reduced reliance on manual literature reviews [13].

3.5 Commercialization

Commercial functions in life sciences are undergoing rapid transformation as companies shift from broad, one-size-fits-all strategies to personalized, data-driven engagement. GenAI is accelerating this shift by enabling content automation, channel optimization, and micro-segmentation at scale. Among all domains, commercialization has the highest projected value capture: **$18–30 billion annually** [1].

Key Application Areas

1. **Omnichannel content creation and localization** *(automate tailored messaging)* GenAI can generate localized, compliant promotional materials across channels - email, digital ads, rep-triggered content - based on clinical data and HCP preferences [1][3].
2. **Next-best-action recommendation** *(optimize rep engagement in real time)* Models synthesize CRM data, channel behavior, prescription trends, and prior interactions to dynamically recommend when, how, and what message a sales rep should deliver [4].
3. **Segmentation and persona modeling** *(refine targeting strategy)* By analyzing behavioral and attitudinal data, GenAI can identify granular HCP personas and match engagement tactics accordingly - improving reach and conversion rates [2][4].
4. **Field force enablement** *(enhance rep performance with AI copilots)* Sales reps are increasingly supported by GenAI tools that summarize patient/HCP profiles, suggest talking points, and respond to medical queries,

allowing for more productive in-person or virtual visits [3].

Illustrative Use Case

Novo Nordisk has leveraged GenAI to scale omnichannel personalization across its diabetes portfolio. By integrating GenAI into its commercial tech stack, the company automated content creation for emails, rep tools, and digital ads tailored to specific HCP segments. The initiative led to a 20% increase in engagement rates and enabled reps to shift time from admin tasks to high-value interactions [14].

Discussion: Key Risks and Adoption Barriers

While the promise of GenAI across life sciences is significant, its broad adoption remains constrained by a set of critical challenges that organizations must address to ensure responsible, scalable impact.

1. **Hallucinations and factual reliability**
   Even state-of-the-art large language models can generate inaccurate or fabricated content, particularly when prompted on complex medical or scientific subjects. Without robust validation mechanisms, such hallucinations pose risks to scientific integrity and regulatory compliance [9].
2. **Lack of regulatory guidance**
   Global regulatory agencies have not yet provided comprehensive frameworks for the use of GenAI in clinical, manufacturing, or commercial contexts. This regulatory uncertainty inhibits deployment in GxP environments and slows investment in high-stakes applications.
3. **Insufficient technical and data foundations**
   Many life sciences organizations lack the necessary data infrastructure, interoperability, or AI talent to deploy GenAI at scale. Fragmented systems, limited labeled datasets, and unstructured documents make integration costly and error-prone.
4. **Security and patient data privacy risks**
   The use of GenAI in handling sensitive clinical or patient data raises significant privacy concerns. Ensuring HIPAA, GDPR, and other compliance standards while leveraging foundation models remains an open technical and governance challenge [2][8].
5. **Organizational resistance and change management**
   Many GenAI use cases require rethinking existing workflows, roles, and incentives. Without strong leadership and operational enablement, even high-ROI pilots risk stalling at the proof-of-concept stage [3][5].

4. Conclusion

Generative AI represents a paradigm shift in how life sciences organizations can discover, develop, and deliver therapies. Its ability to process and synthesize vast, complex data - across structured clinical records, scientific literature, omics datasets, manufacturing logs, and HCP interactions - makes it uniquely suited to solving some of the industry's most persistent bottlenecks. From early discovery to commercialization, GenAI is enabling new levels of automation, insight generation, and decision support.

The observed value from early pilots - ranging from accelerated protocol design and reduced batch deviations to automated medical content generation - signals that GenAI is not merely incremental, but foundational. As the technology matures, it is poised to become a strategic enabler of faster innovation cycles, leaner operations, and more personalized healthcare.

Yet the full realization of this potential is far from guaranteed. Success will require more than technical experimentation: it will demand integrated data ecosystems, fit-for-purpose governance, cross-functional upskilling, and clear change leadership. Companies must also balance innovation with compliance by establishing rigorous validation, monitoring, and auditability frameworks - particularly in regulated, GxP-critical environments.

Ultimately, GenAI will not replace human expertise in life sciences - it will augment it. Organizations that invest now in responsible, scalable adoption will be better positioned to navigate the growing complexity of biomedical innovation and deliver improved outcomes for patients, providers, and stakeholders alike.

References

1. McKinsey & Company. (2024). *Generative AI in the pharmaceutical industry: Moving from hype to reality*; https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-

pharmaceutical-industry-moving-from-hype-to-reality

2. U.S. Food & Drug Administration. (2024). *Using Artificial Intelligence & Machine Learning in the Development of Drug and Biological Products*; https://www.fda.gov/media/167973/download
3. McKinsey & Company. (2023). *Simplification for success: Rewiring the biopharma operating model*; https://www.mckinsey.com/industries/life-sciences/our-insights/simplification-for-success-rewiring-the-biopharma-operating-model
4. Zheng, Y., Koh, H. Y., Yang, M., Li, L., May, L. T., Webb, G. I., Pan, S., & Church, G. (2024). *Large language models in drug discovery and development: From disease mechanisms to clinical trials*. *arXiv*. https://arxiv.org/abs/2409.04481
5. McKinsey & Company. (2024). *Faster, smarter trials: Modernizing biopharma's R&D IT applications*; https://www.mckinsey.com/industries/life-sciences/our-insights/faster-smarter-trials-modernizing-biopharmas-r-and-d-it-applications
6. Nature Reviews Drug Discovery. (2023). *Generative AI and the Future of Early Drug Discovery*; https://www.nature.com/articles/s41573-023-00388-w
7. McKinsey & Company. (2024). *Generative AI in healthcare: Current trends and future outlook*; https://www.mckinsey.com/industries/healthcare/our-insights/generative-ai-in-healthcare-current-trends-and-future-outlook
8. European Medicines Agency. (2024). *Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle*; https://www.ema.europa.eu
9. MIT Technology Review. (2024). *AI hallucinations are poisoning medical science - how can we fix it*; https://www.technologyreview.com
10. Insilico Medicine. (2024). *AI-powered drug discovery platform Chemistry42*; https://insilico.com/chemistry42
11. Pfizer. (2023). *Innovation Through GenAI in Clinical Development*; https://www.pfizer.com
12. Novartis. (2024). *Reimagining Manufacturing with AI-Driven Digital Twins*; https://www.novartis.com
13. AstraZeneca. (2023). *AI in Medical Affairs: Driving Real-Time HCP Engagement*; https://www.astrazeneca.com
14. Novo Nordisk. (2023). *Omnichannel Engagement with GenAI in Diabetes*; https://www.novonordisk.com